A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
BACKGROUND Telisotuzumab adizutecan (ABBV-400, Temab-A) is an antibody-drug conjugate targeting c-Met (MET) protein with adizutecan, a novel topoisomerase 1 inhibitor payload. In monotherapy dose escalation, Temab-A demonstrated a manageable safety profile and promising antitumor activity in advanced colorectal cancer...